Skip to main content
SpringerLink
Log in

SMC says `yes' to six drugs . . .

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. advice is dependent upon availability of a patient access scheme

Reference

  • Scottish Medicines Consortium. SMC advice: abatacept (Orencia); adalimumab (Humira); aflibercept (Eylea); axitinib (Inlyta); botulinum toxin type a (Botox); darunavir (Prezista); insulin degludec (Tresiba); insulin glargine (Lantus); ipilimumab (Yervoy). Internet Document : 8 Apr 2013. Available from: URL: http://www.scottishmedicines.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

SMC says `yes' to six drugs . . .. PharmacoEcon Outcomes News 676, 11 (2013). https://doi.org/10.1007/s40274-013-0337-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0337-2

Search

Navigation